Tenon Medical, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
Condensed Statements of Cash Flows (Unaudited)
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows from Operating Activities | ||
| Net loss | $(3,616) | $(3,576) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 872 | 1,018 |
| Depreciation and amortization | 42 | 100 |
| Provision for credit losses on accounts receivable | — | 10 |
| Amortization of operating right-of-use asset | 65 | 60 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | (23) | (63) |
| Inventory | 11 | (78) |
| Prepaid expenses and other assets | 20 | 29 |
| Accounts payable | 127 | (167) |
| Accrued expenses | 87 | 390 |
| Operating lease liability | (68) | (61) |
| Net cash used in operating activities | (2,483) | (2,338) |
| Cash Flows from Investing Activities | ||
| Purchases of property and equipment | — | (119) |
| Net cash used in investing activities | — | (119) |
| Cash Flows from Financing Activities | ||
| Gross proceeds from issuance of common stock, prefunded warrants and warrants | 4,010 | — |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants under inducement agreement | 3,057 | — |
| Proceeds from issuance of Series A convertible preferred stock | — | 2,605 |
| Proceeds from issuance of common stock | — | 1,990 |
| Offering costs | (808) | (224) |
| Net cash provided by financing activities | 6,259 | 4,371 |
| Effect of foreign currency translation on cash flow | — | 46 |
| Net Increase in Cash and Cash Equivalents | 3,776 | 1,960 |
| Cash and Cash Equivalents at Beginning of Period | 6,535 | 2,428 |
| Cash and Cash Equivalents at End of Period | $10,311 | $4,388 |
| Supplemental Disclosures of Cash Flow Information | ||
| Non-cash investing and financing activities: | ||
| Warrant modification costs | $1,402 | — |
| Preferred stock issued upon conversion of debt and accrued interest | $— | 1,186 |
| Reclassification of deferred offering costs to additional paid-in capital | $110 | 130 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.